Primary Intravitreal Ranibizumab for Myopic Choroidial Neovascularisation

REFERENCES

• Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excises subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992;114:464–472.
   PubMedGoogle Scholar
• Grossniklaus HE, Hutchinson AK, Capone A, et al. Clinicopathologic features of surgically excised choroidal neovascularmembranes. Ophthalmology 1994;101:1099–111
   PubMed Web of Science ®Google Scholar
• Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103(8):1241–1244.
   Google Scholar
• Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003;87:570–3.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 2005;89:1368–70.
   PubMed Web of Science ®Google Scholar
• Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006;26:1093–4.
   PubMedGoogle Scholar
• Yamamoto I, Rogers HA, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Ophthalmol 2007;91:157–60.
   PubMed Web of Science ®Google Scholar
• Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161–5.
   PubMed Web of Science ®Google Scholar
• Laud K, Spaide RF, Freund KB, et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006;26:960–3.
   PubMed Web of Science ®Google Scholar
• Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707–12.
   PubMed Web of Science ®Google Scholar
• Mandal S, Venkatesh P, Sampangi R, et al. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007;17:620–6.
   Google Scholar
• Rheaume M, Sebag M. Intravitreal bevacizumab for the treatment of chorodial neovascularisation associated with pathological myopia. Can J Ophthalmol. 2008; 43 (5):576–580.
   Google Scholar
• Arias L, Planas N, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br. J. Ophthalmol. 2008;92:1035–1039.
   Google Scholar
• Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: Short-term results. Eye. 2009;23:334–338; doi:10.1038/sj.eye.6703052; published online 7 December 2007.
   Google Scholar
• Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: Six-month results of a prospective pilot study. Ophthalmology 2007;114:2190–6.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, et al. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448–451.
   Google Scholar
• Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009 Jan 16 (epub).
   Google Scholar
• Yasushi I, Sayanagi K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: One-year results. American Journal of Ophthal Mol 2009;147(1);94–100.
   Google Scholar
• Gharbiya M, Allievi F, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84–93.
   Google Scholar
• Wong D, Li K. Avastin in myopic chorodial neovascularisation: Is age the limit. Br J Ophthalmol 2008;92(8):1011–12.
   Google Scholar
• Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, Cachulo ML, Carvalheira F, Murta JN. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. 2010 Mar;30(3):407–12.
   Google Scholar
• Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina. 2010 Mar;30(3):399–406.
   Google Scholar
• Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009 Jun;29(6):750–6.
   Google Scholar
• Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009 Mar;247(3):311–8.
   Google Scholar